What drugs does Axogen Corporation make?

Axogen Corporation has 1 FDA-approved drugs including avance nerve graft.

What therapeutic areas does Axogen Corporation focus on?

Axogen Corporation focuses primarily on Oncology.

← Back

Data updated: Nov 8, 2026

Axogen Corporation

Biotech

Oncology

Axogen Corporation is a biotechnology company focused on Oncology. Key products include avance nerve graft.

2025

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Biologics

Axogen Corporation's Key Drugs

Axogen Corporation's core commercial portfolio centers on avance nerve graft, spanning Oncology — its most strategically important drugs approved in the last 15 years.

avance nerve graft

Approved 2025

Axogen Corporation News

All Axogen Corporation news →

Oct 28, 2026 Earnings
Axogen, Inc. Reports Third Quarter 2026 Financial Results ↗
Oct 1, 2026 Deals
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair ↗
Sep 10, 2026 Deals
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock ↗
Sep 10, 2026 Deals
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies ↗

Axogen Corporation's Recent FDA Approvals

Axogen Corporation secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

avance nerve graft BLA

2025-12-03

acellular nerve allograft-arwx

Axogen Corporation's Therapeutic Areas

Axogen Corporation's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%

0 drugs Phase 1: 1

Axogen Corporation's Top Competitors

Axogen Corporation's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.